OncoMatch/Clinical Trials/NCT04135807
Implantable Microdevice In Primary Brain Tumors
Is NCT04135807 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies Microdevice for grade ii glioma.
Treatment: Microdevice — This pilot study will assess the safety and feasibility of using an implantable microdevice to measure local intratumor response to chemotherapy and other clinically relevant drugs in malignant brain tumors. * The device involved in this study is called a microdevice. * The drugs used in this study will only include drugs already used systemically for the treatment of gliomas.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Disease stage
Required: Stage II, III, IV (WHO grade)
Grade: IIIIIIV (WHO)
WHO grade II-IV glioma
Prior therapy
Cannot have received: chemotherapy
Participants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas) prior to entering the study
Cannot have received: radiotherapy
Participants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas) prior to entering the study
Cannot have received: investigational agent
Participants who are receiving any other investigational agents
Lab requirements
Blood counts
Leukocytes ≥ 3,000/mcL; Absolute neutrophil count ≥ 1,500/mcL; Platelets ≥ 100,000/mcL
Kidney function
Creatinine within normal institutional limits OR Creatinine clearance ≥ 60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal
Liver function
Total bilirubin within normal institutional limits; AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional upper limit of normal
Participants must have normal organ and marrow function as defined below: * Leukocytes ≥ 3,000/mcL * Absolute neutrophil count ≥ 1,500/mcL * Platelets ≥ 100,000/mcL * Total bilirubin within normal institutional limits * AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional upper limit of normal * Creatinine within normal institutional limits OR * Creatinine clearance ≥ 60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Brigham and Women's Hospital · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04135807 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, radiotherapy, investigational agent disqualifies patients from enrollment.
What disease stage is eligible?
Stage II or III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages